Human IGFBP-3 Antibody

Catalog #: MAB11488 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB11488-100
MAB11488-SP

Detection of IGFBP‑3 in WM-115 cells (Positive) and U266 cells (Negative).

2 Images

All IGFBP-3 Antibodies

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human IGFBP-3 Antibody Summary

Species Reactivity

Human

Specificity

Detects human IGFBP-3 in ELISAs. In sandwich immunoassays, less than 0.25% cross-reactivity with recombinant human (rh) IGF‑I R, rhIGFBP-1, rhIGFBP-2, rhIGFBP-4, rhIGFBP-5, and rhIGFBP-6 is observed.

Source

Monoclonal Mouse IgG_2B Clone # 1065833

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Mouse myeloma cell line NS0-derived recombinant human IGFBP‑3
Gly28-Lys291
Accession # CAA46087

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.
*Small pack size (-SP) is supplied either lyophilized or as a 0.2 μm filtered solution in PBS. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Immunohistochemistry

3-25 µg/mL

Immersion fixed paraffin-embedded sections of placenta

Immunocytochemistry

3-25 µg/mL

Fixed WM-115 cells (Positive) and absent in U266 human myeloma cell line (Negative)

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Immunocytochemistry/ Immunofluorescence

View Larger

Detection of IGFBP‑3 in WM-115 cells (Positive) and U266 cells (Negative). IGFBP‑3 was detected in fixed WM-115 cells (Positive) and absent in U266 human myeloma cell line (Negative) using Mouse Anti-Human IGFBP‑3 Monoclonal Antibody (Catalog # mab11488) at 8 µg/ml for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to the cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

Immunohistochemistry

View Larger

Detection of IGFBP‑3 in Placenta. IGFBP‑3 was detected in immersion fixed paraffin-embedded sections of placenta using Mouse Anti-Human IGFBP‑3 Monoclonal Antibody (Catalog # mab11488) at 5 µg/ml for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the cytoplasm. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IGFBP-3

The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and at least four additional low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBPs, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Human IGFBP-3 cDNA encodes a 291 amino acid (aa) residue precursor protein with a putative 27 aa residue signal peptide that is processed to generate the 264 aa residue mature protein with three potential N-linked and two potential O-linked glycosylation sites. Human IGFBP-3 is expressed in multiple tissues. The highest expression level is found in the non-paranchymal cells of the liver. Expression levels are also higher during extrauterine life and peak during puberty. Human IGFBP-3 is the major IGF binding protein in plasma where it exists in a ternary complex with IGF-I or IGF-II and the acid-labile subunit (ALS).

References

Jones, J.I. and D.R. Clemmons (1995) Endocrine Rev. 16:3.
Kelley, K.M. et al. (1996) Int. J. Biochem. Cell Biol. 28:619.
Spagnoli, A. and R.G. Rosenfeld (1997) Curr. Op. Endocrinology and Diabetes 4:1.

Long Name

Insulin-like Growth Factor Binding Protein 3

Entrez Gene IDs

3486 (Human); 16009 (Mouse)

Alternate Names

acid stable subunit of the 140 K IGF complex; binding protein 29; binding protein 53; growth hormone-dependent binding protein; IBP-3; IBP3BP-53; IGF-binding protein 3; IGFBP3; IGFBP-3; insulin-like growth factor binding protein 3; insulin-like growth factor-binding protein 3